MedPath

A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections

Phase 2
Completed
Conditions
Soft Tissue Infections
Interventions
Drug: beta-lactam
Drug: Standard care
Registration Number
NCT00303589
Lead Sponsor
Hoffmann-La Roche
Brief Summary

This 3 arm study will compare the efficacy and safety of beta-lactam with that of 'standard care' in patients with complicated skin and skin structure infections requiring hospitalization. Patients will be randomized to receive 1)beta-lactam 750mg iv q8h 2)beta-lactam 1500mg iv q8h or 3)'standard care' \[PRP (nafcillin or flucloxacillin) or vancomycin, plus aztreonam or ciprofloxacin\]. The anticipated time on study treatment is \<3 months and the target sample size is 100-500 individuals.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
313
Inclusion Criteria
  • adult patients, >=18 years of age;
  • skin or skin structure infection requiring hospitalization;
  • clinical diagnosis of a skin or skin structure infection caused by bacteria known or suspected to be susceptible to the randomized study treatment;
  • material from site of infection is clinically purulent or seropurulent.
Exclusion Criteria
  • presenting with sustained shock (SBP<90mm Hg for > 2 hours, despite adequate fluid resuscitation);
  • known or suspected concomitant bacterial infection requiring antibiotic treatment;
  • skin infection or chronic non-healing ulcer of > 2 weeks duration;
  • patients in whom surgery is the primary treatment.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1beta-lactam-
2beta-lactam-
3Standard care-
Primary Outcome Measures
NameTimeMethod
Clinical cure rate.Event driven
Secondary Outcome Measures
NameTimeMethod
Bacteriological outcomeEvent driven
Time to clinical cureEvent driven
Time to resolution of signs and symptoms of skin or soft tissue infectionEvent driven
Adverse events; laboratory abnormalitiesThroughout study

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.